Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Journal: Cancer Research

Published: 2020-05-15

DOI: 10.1158/0008-5472.can-19-3819

Affiliations: 22

Authors: 24

Go to article
Institutions Share
AstraZeneca Cambridge, United Kingdom (UK) 0.17
Yale Department of Pathology, United States of America (USA) 0.12
Yale Cancer Center, United States of America (USA) 0.09
Yale Section of Medical Oncology, United States of America (USA) 0.08
Department of Integrative Oncology, BCCRC, Canada 0.06
Department of Pathology and Laboratory Medicine, UBC, Canada 0.06
Yale Department of Pharmacology, United States of America (USA) 0.06
Yale Cancer Biology Institute (YCBI), United States of America (USA) 0.06
Sandra and Edward Meyer Cancer Center, Cornell University, United States of America (USA) 0.04
Guardant Health, Inc., United States of America (USA) 0.04
Yale Department of Immunobiology, United States of America (USA) 0.04
Nomis Center for Immunobiology and Microbial Pathogenesis, Salk, United States of America (USA) 0.04
Harvard Department of Biostatistics (BIO), United States of America (USA) 0.03
Department of Data Sciences, DFCI, United States of America (USA) 0.03
Pathology and Laboratory Medicine - West Haven, United States of America (USA) 0.02
Rhode Island Hospital, Brown University, United States of America (USA) 0.02
Brown Alpert Medical School (AMS), Brown University, United States of America (USA) 0.02
Harvard Department of Stem Cell and Regenerative Biology (HSCRB), United States of America (USA) 0.01
Center for Cancer Evolution (CCE), DFCI, United States of America (USA) 0.01
Broad Institute of MIT and Harvard, United States of America (USA) 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER